KL and neoplasm: Concomitantly, the co-treatment of E/LPN-KL and miR125/SLN-KL reduced the tumor size in SAS-bearing mice compared with that of CTR, E, E/LPN, and E/LPN-KL (p < 0.001–0.01; Figure 8a,b).